Drug profile · INN
necitumumab
PORTRAZZA
necitumumab (PORTRAZZA) is a epidermal growth factor receptor erbb1 inhibitor. Route of administration: intra-articular, intramuscular, intravitreal. Current US regulatory status: approved.
Drug details — necitumumab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
necitumumab (PORTRAZZA) is a epidermal growth factor receptor erbb1 inhibitor. Route of administration: intra-articular, intramuscular, intravitreal. Current US regulatory status: approved.
Key facts
Mechanism of action
Epidermal growth factor receptor erbB1 inhibitor
Primary target: Epidermal growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is necitumumab?
necitumumab (PORTRAZZA) is a epidermal growth factor receptor erbb1 inhibitor. Route of administration: intra-articular, intramuscular, intravitreal. Current US regulatory status: approved.
What is the brand name for necitumumab?
PORTRAZZA is a marketed brand name for necitumumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of necitumumab?
necitumumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.